Bullman S, Zou T, Meyerson M. Mechanistic Insights into Transmissible Cancers of Mammals. Cancer Cell. 2018;33(4):543-544. doi:10.1016/j.ccell.2018.03.019
Williams DR, Nag PP, Zorn N. Strategies for the synthesis of the novel antitumor agent peloruside A. Curr Opin Drug Discov Devel. 2008;11(2):251-71.
Sharifnia T, Hong AL, Painter CA, Boehm JS. Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chem Biol. 2017;24(9):1075-1091. doi:10.1016/j.chembiol.2017.08.002
Mashl J, Scott AD, Huang K lin, et al. GenomeVIP: a cloud platform for genomic variant discovery and interpretation. Genome Res. 2017;27(8):1450-1459. doi:10.1101/gr.211656.116
Cañadas I, Thummalapalli R, Kim JW, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018;24(8):1143-1150. doi:10.1038/s41591-018-0116-5
Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247-250. doi:10.1038/nature24297
Charlton J, Downing TL, Smith ZD, et al. Global delay in nascent strand DNA methylation. Nat Struct Mol Biol. 2018;25(4):327-332. doi:10.1038/s41594-018-0046-4
McFarland JM, Paolella BR, Warren A, et al. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat Commun. 2020;11(1):4296. doi:10.1038/s41467-020-17440-w
Brooks AN, Choi PS, de Waal L, et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014;9(1):e87361. doi:10.1371/journal.pone.0087361
Maruvka YE, Mouw KW, Karlić R, et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat Biotechnol. 2017;35(10):951-959. doi:10.1038/nbt.3966